# A Drug Kept Pancreatic Cancer Patients Alive Twice as Long. For the First Time, It Covers the Majority of Tumors.

- slug: a-drug-kept-pancreatic-cancer-patients-alive-twice-as-long-for-the-first-time-it-covers-the-majo
- date: 2026-04-16
- category: Biotech & Life Sciences

Daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemo, cutting death risk by 60 percent in a Phase III pancreatic cancer trial. More than 90 percent of pancreatic tumors carry the mutation it targets.

---